RS
FLGT icon

R Squared’s Fulgent Genetics FLGT Stock Holding History

R Squared’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,504
Closed -$250K – 555
2025
Q4 		$250K Sell
9,504
-1,559
-14% -$40.4K 0.12% 281
2025
Q3 		$250K Buy
+11,063
New +$228K 0.11% 315
2025
Q1 		– Sell
-4,030
Closed -$74.4K – 713
2024
Q4 		$74.4K Buy
+4,030
New +$78.7K 0.07% 349

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

R Squared's FLGT Position: Q1 2026 in Review

R Squared sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 9,504 shares — an estimated $250K sold.

R Squared first reported a position in FLGT in Q4 2024 and held it in 3 quarters. The position peaked at $250K in Q3 2025. 158 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • R Squared reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 9,504 Fulgent Genetics shares in Q1 2026, an estimated $250K.
  • R Squared first reported a position in Fulgent Genetics in Q4 2024 and held it in 3 quarters.
  • R Squared's Fulgent Genetics position peaked at $250K in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.